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risk group) based on International Prognostic Scoring System
(IPSS). We evaluated allotransplant outcome in MDS patients
with MK.
Result: A total of 79 MDS patients who underwent allotransplant
were identified. Thirty seven of 79 patients (46.8%) harbored unfa-
vorable karyotypes (23 complex karyotype, 25 abnormal chromo-
some 7). Of 79 patients, 24 (30%) met the criteria of MK. The
median follow-up was 5.1 months (0-242 mo). Twenty-four patients
(30%) relapsed and 59 (74.7%) died during the follow-up duration.
Major causes of death included infection (24%), graft versus host dis-
ease (25%) and relapse (31%). Two-year relapse incidence (RI) and
overall survival (OS) were 36% (95%CI, 23%-49%) and 32% (95%
CI, 22%-43%) respectively. Of 79 patients, patients with MK had
significantly higher 2-year RI (51% VS 28%; p 5 0.01) (95%CI,
28-75% VS 13-43%) and lower 2-year OS (6% VS 41%; p 5 0.02)
(95%CI, 0-24%VS 28-54%) than patients without MK. Due to sig-
nificant overlap betweenMK and unfavorable karyotypes, we further
analyzed the effect of MK in each unfavorable karyotype composite
(unfavorable with MK VS unfavorable without MK). Although the
outcome was not statistically different, patients with both unfavor-
able karyotype and MK had a trend toward higher 2-year RI (51%
VS 38%, hazaard ratio [HR] 1.7, p 5 0.34) and lower 2-year OS
(6%VS 31%,HR 1.5, p5 0.28) compare with patients with unfavor-
able karyotypes without MK.
Conclusion: MK is associated with poor allotransplant outcome
with high relapse incidence and low overall survival in addition to
IPSS unfavorable cytogenetic abnormalities.352
MELPHALAN 140MG/M2 COMBINED WITH TBI2(4)Gy AND FLUDARA-
BINE 125MG/M2 AS CONDITIONING FOR ELDERLY PATIENTS WITH
HEMATOLOGICAL MALIGNANCIES IN UNRELATED BONE MARROW
TRANSPLANTATION IS COMPARABLE IN SAFETY AND EFFECTIVENESS
WITH TBI/CY FOR YOUNGER PATIENTS
Ueki, T., Sato, K., Fujikawa, Y., Shimizu, I., Akahane, D., Sumi, M.,
Ueno, M., Ichikawa, N., Kobayashi, H. Nagano Redcross Hospital,
Nagano, Japan
Background:The optimal conditioning and dosage regimen for un-
related bone marrow transplantation for elderly patients with hema-
tological malignancies remains unknown.
Objective and Methods: Among the 63 cases of unrelated bone
marrow transplantation for hematological malignancies performed
in our department, we compared and examined the safety and effi-
cacy of the most commonly used conditioning regimen for elderly
patients, i.e., fludarabine (Flu) (125mg/m2) + melphalan (Mel)
(140mg/m2) + total body irradiation (TBI) [2(4)Gy] (22 cases; here-
after Flu/Mel/TBI group), with theTBI (12Gy) + cyclophosphamide
(CY) (120mg/kg) regimen (23 cases; hereafter TBI/CY group). For 3
cases in the Flu/Mel/TBI group, TBI was increased to 4Gy from
2Gy due to myelodysplastic syndrome associated with each of mye-
lofibrosis, splenomegaly, and aplastic anemia.
Results: The mean age of patients was 58.5 years (range, 40-66
years) for the Flu/Mel/TBI group and 40 years (range, 21-57 years)
for the TBI/Cy group, with the Flu/Mel/TBI group being signifi-
cantly older (p5 0.002). Acute lymphoblastic leukemia was common
in the TBI/CY group. The number of high risk cases did not signif-
icantly differ between the two groups (Flu/Mel/TBI group, 50%;
TBI/CY group, 30%). There were no differences in the number of
days required for engraftment or to achieve complete donor chime-
rism. Early adverse events higher than grade 3, and bacterial, fungal,
or viral infections within one year were 72.7%, 45.5%, 18.2%, and
45.5% in the Flu/Mel/TBI group, and 73.9%, 26.1%, 17.4%, and
52.2% in the TBI/CY group, with no significant difference between
the groups. Acute and chronic GVHD were observed in 56.5% and
81%of cases in the Flu/Mel/TBI group, and 52.5% and 53.4% in the
TBI/CY group, with the Flu/Mel/TBI group having a significantly
higher incidence of chronic GVHD (p5 0.014). The median obser-
vation period of survivors was 30months for the Flu/Mel/TBI group
and 68 months for the TBI/CY group. Two year overall survival and
relapse-free survival were 72.4% and 59.1% in the Flu/Mel/TBI
group, and 77.5% and 64.1% in the TBI/CY group; and two year
treatment-related mortality and recurrence rate were 14.6% and30.8% in the Flu/Mel/TBI group, and 0% and 35.9% in the TBI/
CY group, with no significant differences between the groups.
Conclusion: Flu/Mel/TBI for elderly individuals with hematologi-
cal malignancies proved to be as effective and safe as TBI/CY for
younger patients.
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A PROSPECTIVE RANDOMIZED STUDY COMPARING REDUCED-INTEN-
SITY CONDITIONING AND MYELOABLATIVE CONDITIONING IN PA-
TIENTS WITH MYELOID LEUKEMIA UNDERGOING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Ringden, O.1, Erkers, T.1, Aschan, J.2, Le Blanc, K.3, Hagglund, H.4,
Omazic, B.1, Svenberg, P.1, Ljungman, P.4, Mattsson, J.1,
Remberger, M.1 1Karolinska Institutet, Stockholm, Sweden; 2Karolinska
University Hospital Huddinge, Stockholm, Sweden; 3Karolinska Institu-
tet, Stockholm, Sweden; 4Karolinska University Hospital Huddinge,
Stockholm, Sweden
There have been no randomized studies comparing myeloablative
conditioning (MAC) and reduced-intensity conditioning (RIC) in al-
logeneic hematopoietic stem cell transplantation (HSCT). We
wanted to compare the safety and efficacy of these two regimens.
We performed an open-labeled, randomized, controlled phase-III
trial. Over a 10-year period, adult patients#60 years of age with my-
eloid leukemia were randomised (1:1) to undergo RIC (n 5 18) or
MAC (n 5 19). We included recipients of HLA-A, HLA-B, or
HLA-DRB1-identical unmanipulated grafts from related or unre-
lated donors. The primary endpoint was transplant-relatedmortality
(TRM). Secondary endpoints included relapse, survival, chimerism,
and toxicity.
The RIC patients had faster platelet engraftment (p\0.01), re-
quired fewer erythrocyte and platelet transfusions (p\0.001), and re-
quired less total parenteral nutrition (TPN) than the MAC group
(p\0.01). Cytomegalovirus reactivation was commoner in the
MAC group (14/19) than in the RIC group (6/18) (p5 0.02). Hem-
orrhagic cystitis occurred in eight of the MAC patients and in none
of the RIC patients (p\0.01). Donor chimerism was similar in the
two groups regarding CD19 and CD33, but was delayed for CD3
in the RIC group. Later chimerism status was similar. Incidences
of acute and chronic graft-versus-host disease (GVHD) were similar
in the two groups, but twoMACpatients and no RIC patients died of
GVHD. Five-year TRM was around 11% in both groups, and re-
lapse and survival were not significantly different. TheMACpatients
with intermediate cytogenetic acute myeloid leukemia had a three-
year survival of 73%, as compared to 90% in the RIC patients.
TRMwas lowwith RIC andMAC. Although few patients were in-
cluded, RIC had several advantages such as faster platelet engraft-
ment, fewer transfusions, less TPN, fewer CMV reactivations, and
less hemorrhagic cystitis.
354
OUTCOME OF HIGH-RISK AND REFRACTORY AML/MDS PATIENTS RE-
CEIVING A FLAMSA SEQUENTIAL CHEMOTHERAPY REGIMEN FOLLOWED
BY REDUCED-INTENSITY CONDITIONING (RIC) AND ALLOGENEIC HEM-
ATOPOEITIC STEM CELL TRANSPLANTATION (allo-HSCT)
Detrait, M.1, Chevallier, P.2, Sobh, M.1, Guillaume, T.2, Thomas, X.1,
Morisset, S.1, Tedone, N.1, Delaunay, J.2, Nicolini, F.1, Ducastelle, S.1,
Chelghoum, Y.1, Barraco, F.1, Labussiere, H.1, Mohty, M.2,
Michallet, M.1 1Centre Hospitalier Lyon Sud, Pierre Benite, France; 2Ho-
tel Dieu Hospital, University of Nantes, Nantes, France
This retrospective analysis aimed to assess the outcome of 40 pa-
tients with refractory or high risk AML/MDS who received
FLAMSA sequential chemotherapy. There were 30 males and 10 fe-
males with a median age of 52 years (32-66). Diseases characteristics
were: progressive or refractory disease after rescue treatment for first
relapse (n 5 21), early relapse without any further salvage therapy
(n 5 4), and primary induction failure (n 5 4). The series also in-
cluded 7 patients with high risk MDS and 4 patients in first CR
but having a very poor prognosis. The FLAMSA regimen included
Fludarabine (30 mg/m2/d), cytarabine (2 g/m2/d) and amsacrine
(100mg/m2/d) from day -12 to day -9. After 3 days of rest, a RIC reg-
imen was administered. In 28 patients, the RIC regimen included 4
